MMSc

LifeScan Launches OneTouch® Solutions, A Holistic Digital Health Offering Linking People with Diabetes to Solutions and Support From Proven Experts

Retrieved on: 
Monday, October 25, 2021
People, Solution, Sleep, Quality of life, Technology, Goal, Knowledge, Hypertension, Motivation, American Association of Clinical Endocrinologists, LifeScan, Diabetes, Blood, Physician, Habit, Prediabetes, History, Obesity, Caregiver, Blue star, Insulin, E-commerce, Trust, A1C, OneTouch Ultra, Exercise, LDL, Heart failure, Asbury, LLC, Reinier Nooms, Trial of the century, Diet, Awareness, Health, Nursing, Research, Warshaw, Risk, Prevalence, MMSc, Pharmaceutical industry, Medical device

"Proven digital tools and technologies can offer the critical support people need and ease the burdens of diabetes management for both the person with diabetes and their healthcare providers," added Warshaw.

Key Points: 
  • "Proven digital tools and technologies can offer the critical support people need and ease the burdens of diabetes management for both the person with diabetes and their healthcare providers," added Warshaw.
  • Cecelia Health provides a one-on-one virtual support program for diabetes management and other health concerns, needs and questions delivered by Certified Diabetes Care and Education Specialists.
  • More than 20 million people and their caregivers around the world count on LifeScan's OneTouch brand products to manage their diabetes.
  • Together, LifeScan and OneTouch improve the quality of life for people with diabetes with products and digital platforms defined by simplicity, accuracy, and trust.

The Worldwide Teal Pumpkin Project is Back to Help Children With Food Allergies Participate Safely in Halloween Trick-or-Treating

Retrieved on: 
Thursday, September 30, 2021
Candy, Hope, Instagram, FARE, Degenerative disease, Residential treatment center, Health, MMSc, Map, Associate Director of National Intelligence and Chief Information Officer, Food Allergy Research & Education, Twitter, Legislation, Milk, Awareness, Disease, Food allergy, COVID-19, Facebook, Research, Food, Thermo Fisher Scientific, Allergy, Quality of life, Tourism, Public relations, Vaccine

McLEAN, Va., Sept. 30, 2021 /PRNewswire/ --Halloween trick-or-treating is back in 2021, and so is the Teal Pumpkin Project to help trick-or-treaters with food allergies find safe treats in their neighborhood.

Key Points: 
  • McLEAN, Va., Sept. 30, 2021 /PRNewswire/ --Halloween trick-or-treating is back in 2021, and so is the Teal Pumpkin Project to help trick-or-treaters with food allergies find safe treats in their neighborhood.
  • Many traditional Halloween treats aren't safe for children with food allergies as popular Halloween candies can contain nuts, milk, egg, soy, wheat or sesame.
  • A new Neighborhood Captain program is being created to help spread awareness of the Teal Pumpkin Project within local communities.
  • "We are so grateful for the support of Allery Insider as the first title sponsor of the Teal Pumpkin Project."

TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances

Retrieved on: 
Thursday, September 23, 2021
Therapy, LinkedIn, Paramount, Dana–Farber Cancer Institute, Follicular lymphoma, RMS, Infection, Degenerative disease, PI3K, Immunity, MMSc, NASDAQ, FDA, Patient, Differentiable function, CK1, NHL, MD, Umbralisib, Adult, Division, Toxicity, Lymphoid leukemia, Acquisition, Company, CLL, TG, American Society of Hematology, Cell proliferation, PDUFA, Survival, Safety, Clinical research, Manuscript, Time, Multiple sclerosis, Chronic lymphocytic leukemia, Society, GLOBE, Pharmaceutical industry

Michael S. Weiss, the Companys Chairman and Chief Executive Officer stated, We are pleased that the integrated safety analysis of 371 patients treated with UKONIQ has been published in Blood Advances.

Key Points: 
  • Michael S. Weiss, the Companys Chairman and Chief Executive Officer stated, We are pleased that the integrated safety analysis of 371 patients treated with UKONIQ has been published in Blood Advances.
  • The integrated safety data analysis of umbralisib published [today/yesterday] is encouraging for patients, especially given the low rate of discontinuations due to adverse events observed.
  • These data are described further in the manuscript entitled, Integrated safety analysis of umbralisib, a dual PI3K/CK1 inhibitor, in relapsed/refractory lymphoid malignancies, which was published online in Blood Advances.
  • UKONIQ is a trademark ofTG Therapeutics, Inc.
    UKONIQ is the first and onlyoral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon.

Exacis Biotherapeutics Announces Key Additions To Company's Scientific Advisory Board

Retrieved on: 
Friday, September 10, 2021

Dr. Munster has extensive experience consulting with biotechnology companies to develop oncology treatments and joins the SAB to assist Exacis in developing products aimed at treating solid tumors, including breast malignancies.

Key Points: 
  • Dr. Munster has extensive experience consulting with biotechnology companies to develop oncology treatments and joins the SAB to assist Exacis in developing products aimed at treating solid tumors, including breast malignancies.
  • Dr. Jacobsonhas extensive experience with cell therapy development and use and joins the SAB to assist Exacis in developing products aimed at treating hematologic malignancies.
  • Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary mRNA based technology.
  • Exacis uses the technology to generate iPSCs and to edit their genome to create stealthed, performance enhancedallogeneic NK and T cell products, termed ExaNK, ExaCAR-NK and ExaCAR-T cells.

Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards

Retrieved on: 
Friday, September 10, 2021
Health, Other Science, Clinical Trials, General Health, Cardiology, Science, Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Bayer, PULMONARY ARTERIAL HYPERTENSION (PAH), CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH), BAYER

Bayer announced the 2020 recipients of the annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary hypertension (PH), with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

Key Points: 
  • Bayer announced the 2020 recipients of the annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary hypertension (PH), with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
  • The PHAB Awards in recognizing the dedicated efforts of worthy researchers, underscores Bayers commitment to health for all.
  • Samuel Rayner, M.D., University of Washington Center for Lung Biology, to study proximal pulmonary vascular compliance and inflammation in PAH.
  • Our online press service is just a click away: www.bayer.us/en/newsroom
    BAYER and the Bayer Cross are registered trademarks of Bayer.

Digital Therapeutic Relieves PTSD Symptoms in 88 Percent of Military Veterans and Sexual Assault Victims Studied

Retrieved on: 
Wednesday, September 8, 2021

Moreover, 48% of subjects experienced remission from PTSD two months after treatment, and that number increased to 50% at six months post-treatment.

Key Points: 
  • Moreover, 48% of subjects experienced remission from PTSD two months after treatment, and that number increased to 50% at six months post-treatment.
  • Nearly 9 million people in the U.S. struggle with PTSD, including 470,000 military veterans.
  • As an alternative to medications and therapy, Freespira's at-home, twice daily, 17-minute treatments stabilize breathing patterns to reduce or eliminate symptoms.
  • The published study did not reveal the sex or military experience of participants who experienced sexual assault.

LightForce Orthodontics Hires Amazon Executive Kelly Riedel as Chief Operating Officer

Retrieved on: 
Monday, August 9, 2021
Slate, BA, Delaware General Corporation Law, Patient, USD, Orthodontics, UC Berkeley School of Optometry, III, Robotics, Mortification (band), CEO, Matrix Partners, Amazon Robotics, Houghton Mifflin Harcourt, Industry, Entrepreneurship, 3D, University, Learning, Head, Mawarid Finance, Amazon (company), Technology, Delaware, Skadden, Automation, Doctor of Philosophy, Innovation Hub, Fourth Industrial Revolution, Middlebury College, Research, Amazon, DMD, Miracles (TV series), MMSc, Management, 3D printing

BURLINGTON, Mass., Aug. 9, 2021 /PRNewswire-PRWeb/ -- LightForce Orthodontics ,makers of the world's first and only fully customizable 3D-printed bracket system in the massive global orthodontics market (projected to reach USD $9.72 Billion by 2026 ), today announced it has appointed veteran Amazon.com executive Kelly Cunning Riedel as its first Chief Operating Officer.

Key Points: 
  • BURLINGTON, Mass., Aug. 9, 2021 /PRNewswire-PRWeb/ -- LightForce Orthodontics ,makers of the world's first and only fully customizable 3D-printed bracket system in the massive global orthodontics market (projected to reach USD $9.72 Billion by 2026 ), today announced it has appointed veteran Amazon.com executive Kelly Cunning Riedel as its first Chief Operating Officer.
  • "Kelly Riedel will make a powerful addition to the LightForce executive team.
  • It's an incredible group, on an exciting trajectory, with a powerful mission: One Size Fits One," said Kelly Riedel.
  • LightForce Orthodontics, Inc. is the inventor, manufacturer, and provider of a digital platform providing orthodontists with patented fully customized, 3D-printed tooth-moving tools.